CD59 blocks not only the insertion of C9 into MAC but inhibits ion channel formation by homologous C5b-8 as well as C5b-9

Journal of Physiology

Volumn 539, Issue 2, 2002, Pages 537-545

  Farkas, Imre ^a,c   Baranyi, Lajos ^b,f   Ishikawa, Yasushige ^b   Okada, Noriko ^a   Bohata, Csaba ^c   Budai, Denes ^d   Fukuda, Atsuo ^e   Imai, Masaki ^a   Okada, Hidechika ^a  

^a NAGOYA CITY UNIV MEDICAL SCHOOL   (Japan)

^b NAGOYA CITY UNIVERSITY   (Japan)

^c UNIVERSITY OF SZEGED   (Hungary)

^d UNIVERSITY OF SZEGED   (Hungary)

^e HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^f WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD59 ANTIGEN; COMPLEMENT COMPONENT C9; COMPLEMENT MEMBRANE ATTACK COMPLEX; ION CHANNEL; MEMBRANE PROTEIN; COMPLEMENT COMPONENT C5B; COMPLEMENT COMPONENT C5B 8; UNCLASSIFIED DRUG;

ARTICLE; B LYMPHOCYTE; CELL MEMBRANE; CELL MEMBRANE CONDUCTANCE; CELL MEMBRANE STEADY POTENTIAL; CHANNEL GATING; CONTROLLED STUDY; HUMAN; HUMAN CELL; ION CONDUCTANCE; MOLECULAR SIZE; PATCH CLAMP; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; STEADY STATE; COMPLEMENT ACTIVATION; CONDUCTANCE; HUMAN TISSUE; ION CURRENT; LYMPHOCYTE MEMBRANE; MEMBRANE CURRENT; WHOLE CELL PATCH CLAMP;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD59; B-LYMPHOCYTES; CELL LINE; CELL MEMBRANE; COMPLEMENT C9; COMPLEMENT MEMBRANE ATTACK COMPLEX; COMPLEMENT SYSTEM PROTEINS; FLOW CYTOMETRY; HUMANS; ION CHANNELS; PATCH-CLAMP TECHNIQUES; RABBITS;

EID: 0036521875     PISSN: 00223751     EISSN: None     Source Type: Journal    
DOI: 10.1113/jphysiol.2001.013381     Document Type: Article

References (50)

1. AKATSU, H., YAMADA, T., OKADA, N., YAMAMOTO, T., YAMASHINA, M. & OKADA, H. (1997). Unique expression of HRF20 (CD59) in human nervous tissues. Microbiology and Immunology 41, 321-329.
2. BORA, N. S., GOBLEMAN, C. L., ATKINSON, J. P., PEPOSE, J. S. & KAPLA, H. (1993). Differential expression of the complement regulatory proteins in the human eye. Investigation in Ophthalmology and Visual Sciences 34, 3579-3584.
3. CHANG, C., HUSLER, T., ZHAO, J., WIEDMER, T. & SIMS, P. J. (1994) Identity of a peptide domain of human C9 that is bound by the cell-surface complement inhibitor, CD59. Journal of Biological Chemistry 269, 26424-26430.
4. DAVIES, A., SIMMONS, D. L., HALE, G., HARRISON, R. A., TIGHE, H., LACHMANN, P. J. & WALDMANN, H. (1989). CD59, an Ly-6-like protein expressed in human lymphoid cells, regulates the action of the complement membrane attack complex on homologous cells. Journal of Experimental Medicine 170, 637-654.
5. DISCIPIO, R. G. (1998). Late components. In The Complement System, 2nd edn, ed. ROTHER, K., TILL, G. O. & HANSCH, G. M., pp. 50-68. Springer Verlag, Berlin, Heidelberg.
6. FLETCHER, C. M., HARRISON, R. A., LACHMANN, P. J. & NEUHAUS, D. (1994). Structure of a soluble, glycosylated form of the human complement regulatory protein CD59. Structure 185, 185-199.
7. FUJITA, T., INOUE, T., OGAWA, K., IIDA, K. & TAMURA, N. (1987). The mechanism of action of decay-accelerating factor (DAF). DAF inhibits the assembly of C3 convertases by dissociating C2a and Bb. Journal of Experimental Medicine 155, 1221-1228.
8. GUC, D., CANPINAR, H., KUCUKAKSU, C. & KANSU, E. (2000). Expression of complement regulatory proteins CR1, DAF, MCP and CD59 in haematological malignancies. European Journal of Haematology 64, 3-9.
9. HANSCH, G. M. & SHIN, M. L. (1998). Complement attack phase. In The Complement System, 2nd edn, ed. ROTHER, K., TILL, G. O. & HANSCH, G. M., pp. 115-146. Springer Verlag, Berlin, Heidelberg.
10. HARADA, R., OKADA, N., FUJITA, T. & OKADA, H. (1990). Purification of 1F5 antigen that prevents complement attack on homologous cell membranes. Journal of Immunology 144, 1823-1828.
11. HILLE, B. (1994). Ionic Channels of Excitable Membranes, 2nd edn. Sinauer Associates, Sunderland, MA, USA.
12. KIEFFER, B., DRISCOLL, P. C., CAMPBELL, I. D., WILLIS, A. C., VAN DER MERWE, P. A. & DAVIS, S. J. (1994). Three-dimensional solution structure of the extracellular region of the complement regulatory protein CD59, a new cell-surface protein domain related to snake venom neurotoxins. Biochemistry 33, 4471-4482.
13. KILGORE, K. S., SCHMID, E., SHANLEY, T. P., FLORY, C. M., MAHESWARI, V., TRAMONTINI, N. L., COHEN, H., WARD, P. A., FRIEDL, H. P. & WARREN, J. S. (1997). Sublytic concentration of the membrane attack complex of complement induce endothelial interleukin-8 and monocyte chemoattractant protein-1 through nuclear factor-kappaB activation. American Journal of Pathology 150, 2019-2031.
14. LISZEWSKI, M. K. & ATKINSON, J. P. (1998). Membrane cofactor protein (CD46) and decay accelerating factor (CD55). In The Complement System, 2nd edn, ed. ROTHER, K., TILL, G. O. & HANSCH, G. M., pp. 146-163. Springer Verlag, Berlin, Heidelberg.
15. LOCKERT, D. H., KAUFMAN, K. M., CHANG, C., HUSLER , T., SODETZ, J. M. & SIMS, P. J. (1995). Identity of the segment of human complement C8 recognized by complement regulatory protein CD59. Journal of Biological Chemistry 270, 19723-19728.
16. McGEER, P. L., WALKER, D. G., AKIYAMA, H., KAWAMATA, T., GUAN, A. L. & PARKER, C. J. (1991). Detection of the membrane inhibitor of reactive lysis (CD59) in diseased neurons of Alzheimer brain. Brain Research 544, 315-319.
17. MERI, S., MORGAN, B. P., DAVIES, A., DANIELS, R. H., OLAVESSEN, M. G., WALDMANN, H. & LACHMANN, P. J. (1990). Human protectin (CD59), an 18,000-20,000 MW complement lysis restricting factor, inhibits C5b-8 catalysed insertion of C9 into lipid bilayers. Immunology 71, 1-9.
18. MERI, S., WALDMANN, H. & LACHMANN, P. J. (1991). Distribution of protectin (CD59), a complement membrane attack inhibitor, in normal human tissues. Laboratory Investigation 65, 532-537.
19. MORGAN, B. P. (1988). Non-lethal complement membrane-attack on human neutrophils: transient cell swelling and metabolic depletion. Immunology 63, 71-77.
20. MORGAN, B. P. (1989). Mechanism of tissue damage by the membrane attack complex of complement. Comparative Inflammation 6, 104-111.
21. MORGAN, B. P. (1994). Clinical complementology: recent progress and future trends. European Journal of Clinical Investigation 24, 219-228.
22. MORGAN, B. P. (1999). Regulation of the complement membrane attack pathway. Critical Reviews in Immunology 19, 173-198.
23. MORGAN, B. P., DANKERT, J. R. & ESSER, A. F. (1987). Recovery of human neutrophils from complement attack: removal of the membrane attack complex by endocytosis and exocytosis. Journal of Immunology 138, 246-253.
24. MORGAN, B. P. & GASQUE, P. (1996). Expression of complement in the brain: role in health and disease. Immunology Today 17, 461-466.
25. NICULESCU, F., RUS, H., VAN BIESEN, T. & SHIN, M. L. (1997). Activation of Ras and mitogen-activated protein kinase pathway by terminal complement complexes is G-protein dependent. Journal of Immunology 158, 4405-4412.
26. NOSE, M., KATOH, M., OKADA, N., KYOGOKU, M. & OKADA, H. (1990). Tissue distribution of HRF20, a novel factor preventing the membrane attack of homologous complement, and its predominant expression on endothelial cells in vivo. Immunology 70, 145-149.
27. OKADA, N., HARADA, R., FUJITA, T. & OKADA, H. (1989a). A novel membrane glycoprotein capable of inhibiting membrane attack by homologous complement. International Immunology 1, 205-208.
28. OKADA, N., HARADA, R., FUJITA, T. & OKADA, H. (1989b). Monoclonal antibodies capable of causing hemolysis of neuraminidase-treated human erythrocytes by homologous complement. Journal of Immunology 143, 2262-2266.
29. OKADA, N., HARADA, R. & OKADA, H. (1990). Erythrocytes of patients with paroxysmal nocturnal haemoglobinuria acquire resistance to complement attack by purified 20-kD homologous restriction factor. Clinical and Experimental Immunology 80, 109-113.
30. OKADA, H., NAGAMI, Y., TAKAHASHI, K., OKADA, N., HIDESHIMA, T., TAKIZAWA, H. & KONDO, J. (1989c). 20 kDa homologous restriction factor of complement resembles T cell activating proteins. Biochemical and Biophysical Research Communications 162, 1553-1559.
31. OKADA, H. & OKADA, N. (1998). Membrane-bound inhibitors of C5b-9. In The Complement System, 2nd edn, ed. ROTHER, K., TILL, G. O. & HANSCH, G. M., pp. 174-178. Springer Verlag, Berlin, Heidelberg.
32. OKADA, H. & TANAKA, H. (1983). Species-specific inhibition by glycophorins of complement activation via the alternative pathway. Molecular Immunology 20, 1233-1236.
33. OKADA, H., TANAKA, H. & OKADA, N. (1983). Prevention of complement activation on the homologous cell membrane of nucleated cells as well as erythrocytes. European Journal of Immunology 13, 340-344.
34. REITER, Y., CIOBOTARU, A. & FISHELSON, Z. (1992). Sublytic complement attack protects tumor cells from lytic doses of antibody and complement. European Journal of Immunology 22, 1207-1213.
35. ROLLINS, S. A. & SIMS, P. J. (1990). The complement-inhibitory activity of CD59 resides in its capacity to block incorporation of C9 into membrane C5b-9. Journal of Immunology 144, 3478-3483.
36. ROLLINS, S. A., ZHAO, J., NINOMIYA, H. & SIMS, P. J. (1991). Inhibition of homologous complement by CD59 is mediated by a species-selective recognition conferred through binding to C8 within C5b-8 or C9 within C5b-9. Journal of Immunology 146, 2345-2351.
37. RUS, H., NICULESCU, F. & SHIN, M. L. (1996). Sublytic complement attack induces cell cycle in oligodendrocytes. Journal of Immunology 156, 4892-4900.
38. SCOLDING, N. J., MORGAN, B. P., HOUSTON, W. A. J., LININGTON, C., CAMPBELL, A. K. & COMPSTON, D. A. S. (1989). Vesicular removal by oligodendrocytes of membrane attack complexes formed by activated complement. Nature 339, 620-622.
39. SEYA, T., HARA, T., MATSUMOTO, M. & AKEDO, H. (1990). Quantitative analysis of membrane cofactor protein (MCP) of complement. High expression of MCP on human leukemia cell lines, which is down-regulated during cell differentiation. Journal of Immunology 145, 238-245.
40. SHEN, Y., HALPERIN, J. A. & LEE, C. (1995). Complement-mediated neurotoxicity is regulated by homologous restriction. Brain Research 671, 282-292.
41. SINGHRAO, S. K., NEAL, J. W., MORGAN, B. P. & GASQUE, P. (1999b). Increased complement biosynthesis by microglia and complement activation on neurons in Huntington's disease. Experimental Neurology 159, 362-376.
42. SINGHRAO, S. K., NEAL, J. W., RUSHMERE, N. K., MORGAN, B. P. & GASQUE, P. (1999a). Differential expression of individual complement regulators in the brain and choroid plexus. Laboratory Investigation 79, 1247-1259.
43. SOANE, L., RUS, H., NICULESCU, F. & SHIN, M. L. (1999). Inhibition of oligodendrocyte apoptosis by sublytic C5b-9 is associated with enhanced synthesis of Bcl-2 and mediated by inhibition of caspase-3 activation. Journal of Immunology 163, 6132-6138.
44. STEFANOVA, I, HILGERT, I, KRISTOFOVA, H., BROWN, R., LOW, M. G. & HOREJSI, V. (1989). Characterization of a broadly expressed human leukocyte surface antigen MEM-43 anchored in membrane through phosphatidylinositol. Molecular Immunology 26, 153-161.
45. VISVANATHAN, S. & McNEIL, H. P. (1999). Cellular immunity to the beta 2-glycoprotein-1 in patients with the antiphospholipid syndrome. Journal of Immunology 162, 6919-6925.
46. YAMASHINA, M., UEDA, E., KINOSHITA, T., TAKAMI, T., OJIMA, A., ONO, H., TANAKA, H., KONDO, N., ORII, T., OKADA, N., OKADA, H., INOUE, K. & KITANI, T. (1990). Inherited complete deficiency of 20-kilodalton homologous restriction factor (CD59) as a cause of paroxysmal nocturnal hemoglobinuria. New England Journal of Medicine 323, 1184-1189.
47. YASOJIMA, K., McGEER, E. G. & McGEER, P. L. (1999). Complement regulators C1 inhibitor and CD59 do not significantly inhibit complement activation in Alzheimer disease. Brain Research 833, 297-301.
48. YU, J., ABAGYAN, R., DONG, S., GILBERT, A., NUSSENZWEIG, V. & TOMLINSON, S. (1997). Mapping the active site of CD59. Journal of Experimental Medicine 185, 745-753.
49. ZALMAN, L. S. & MULLER-EBERHARD, H. J. (1990). Comparison of channels formed by poly C9, C5b-8 and the membrane attack complex of complement. Molecular Immunology 27, 533-537.
50. ZHANG, K., JUNIKKALA, S., ERLANDER, M. G., GUO, H., WESTBERG, J. A., MERI, S. & ANDERSSON, L. C. (1998). Up-regulated expression of decay-accelerating factor (CD55) confers increased complement resistance to sprouting neural cells. European Journal of Immunology 28, 1189-1196.